The Brief Report titled “Association of Low-Dose Triple Combination Therapy vs Usual Care With Time at Target Blood Pressure: A Secondary Analysis of the TRIUMPH Randomized Clinical Trial,”1 published on April 13, 2022, was corrected to fix a typographical error in the Abstract Results section. In the sentence, “Those receiving the triple pill achieved a consistently higher time at target at all follow-up periods compared with those receiving usual care (mean [SD]: 0-6 weeks, 36.3% [30.9%] vs 21.7% [28.9%]; P < .001; 6-12 weeks, 5.2% [31.9%] vs 33.7% [33.0%]; P < .001; 12-24 weeks, 66.0% [31.1%] vs 43.5% [34.3%]; P < .001),” 5.2% was corrected to 55.2%.
1.Gnanenthiran
SR, Wang
N, Di Tanna
GL,
et al. Association of low-dose triple combination therapy vs usual care with time at target blood pressure: a secondary analysis of the TRIUMPH randomized clinical trial.
JAMA Cardiol. 2022;7(6):1-6. doi:
10.1001/jamacardio.2022.0471Google ScholarCrossref